That is, biologics/small molecule agent combination therapy, to the extent that it reduces both immunogenicity and a high inflammatory burden, has the potential to minimize steroid exposure, induce remission, and avoid colectomy by facilitating a safe transition to maintenance therapy
ABSTRACT: Since the approval of the first dipeptidyl peptidase-4 (DPP-4) inhibitor in the United States in 2006, the use of these agents as second-line oral antihyperglycemic therapy in type 2 diabetes management has been established
However, in many other countries, including the United States, it is not approved by regulatory agencies for prescription or over-the-counter use
Women of childbearing age should undergo pregnancy testing before use and use contraception during treatment
Management of Takayasu arteritis